|
|
||||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
Variola
virus, the most virulent member of the genus Orthopoxvirus, specifically
infects humans and causes smallpox. Although smallpox was eradicated in 1980,
it remains a potential agent for bioterrorism. As a category A biological
weapon, its potential to devastate populations is a concern. Moreover,
despite the efficacy of a live vaccinia virus
vaccine, the level of toxicity is deemed unacceptably high due in part to the
fact that a live vaccine can be lethal to immunosuppressed
individuals such as those with HIV/AIDS, and that severe complications are
also frequent when eczema arepre-existing
conditions of the vacine. Dartmouth researchers have now found that by combining a
replication-deficient modified vaccinia Ankara
strain (MVA) of vaccinia virus with a toll-like
receptor (TLR) agonist, and optionally an agonistic anti-CD40 monoclonal
antibody, cytolytic T lymphocyte, IFN-gamma
cytokine, and neutralizing antiviral antibody responses to MVA can be
enhanced. Given the reduced toxicity and replication defective nature of the
MVA, vaccines can be developed to prevent or treat variola
virus infection, or related poxvirus infection, in healthy and immunosuppressed individuals or to diminish viral
pathogenesis. In addition, the
one-shot approach developed also allows for ring immunization in response to
a bioterrorist smallpox virus release.
This technology is claimed in a pending patent
application. We are seeking an industrial partner interested in its
commercialization. (Ref: J334) |
||
|
|
|
|
|
|
|
|
|
«Technology Transfer Office : Sponsored Projects : Dartmouth College |
||
|
|
||||
|
|
||||
|
|
Phone: (603) 646-3027 |
|||
|
|
|
|
Fax: (603) 646-3670 |
|
